US Patent Issued to Novartis, Intellia Therapeutics on Feb. 24 for "Compositions and methods for the treatment of hemoglobinopathies" (Massachusetts, California Inventors)

ALEXANDRIA, Va., Feb. 24 -- United States Patent no. 12,559,748, issued on Feb. 24, was assigned to Novartis AG (Basel, Switzerland) and Intellia Therapeutics Inc. (Cambridge, Mass.).

"Compositions and methods for the treatment of hemoglobinopathies" was invented by Craig Stephen Mickanin (Hopkinton, Mass.), Christian Schmedt (El Cerrito, Calif.), Jennifer Snead (San Diego), Susan C. Stevenson (Ashland, Mass.) and Yi Yang (Belmont, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention is directed to genome editing systems, reagents and methods for the treatment of hemoglobinopathies."

The patent was filed on June 24, 2022, under Application No. 17/808,802.

*For further information, inc...